192 related articles for article (PubMed ID: 12952292)
21. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Puri RK
Croat Med J; 2003 Aug; 44(4):455-62. PubMed ID: 12950150
[TBL] [Abstract][Full Text] [Related]
23. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice.
Kawakami K; Kawakami M; Snoy PJ; Husain SR; Puri RK
J Exp Med; 2001 Dec; 194(12):1743-54. PubMed ID: 11748276
[TBL] [Abstract][Full Text] [Related]
24. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
25. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma.
Joshi BH; Husain SR; Puri RK
Drug News Perspect; 2000 Dec; 13(10):599-605. PubMed ID: 12879131
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.
Joshi BH; Plautz GE; Puri RK
Cancer Res; 2000 Mar; 60(5):1168-72. PubMed ID: 10728667
[TBL] [Abstract][Full Text] [Related]
28. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
29. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model.
Shimamura T; Fujisawa T; Husain SR; Kioi M; Nakajima A; Puri RK
J Immunol; 2008 Oct; 181(7):4656-65. PubMed ID: 18802068
[TBL] [Abstract][Full Text] [Related]
30. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
31. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
Kawakami M; Kawakami K; Puri RK
Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
Candolfi M; Xiong W; Yagiz K; Liu C; Muhammad AK; Puntel M; Foulad D; Zadmehr A; Ahlzadeh GE; Kroeger KM; Tesarfreund M; Lee S; Debinski W; Sareen D; Svendsen CN; Rodriguez R; Lowenstein PR; Castro MG
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20021-6. PubMed ID: 21030678
[TBL] [Abstract][Full Text] [Related]
33. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
34. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
[TBL] [Abstract][Full Text] [Related]
35. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
Kawakami K; Kawakami M; Puri RK
Clin Cancer Res; 2004 Aug; 10(15):5264-70. PubMed ID: 15297430
[TBL] [Abstract][Full Text] [Related]
38. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex.
Miloux B; Laurent P; Bonnin O; Lupker J; Caput D; Vita N; Ferrara P
FEBS Lett; 1997 Jan; 401(2-3):163-6. PubMed ID: 9013879
[TBL] [Abstract][Full Text] [Related]
39. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.
Liu TF; Cai J; Gibo DM; Debinski W
Clin Cancer Res; 2009 Jan; 15(1):160-8. PubMed ID: 19118043
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
Saito M; Murata T; Watanabe K; Kawakami K; Suzuki M; Koji T; Puri RK; Kitazato K; Kobayashi N
Int J Cancer; 2005 Aug; 116(1):1-8. PubMed ID: 15756691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
